The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA
beta-thujone inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]; beta-thujone inhibits the reaction [Choline results in increased activity of CHRNA7 protein]
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA
Camphor results in increased activity of TRPV3 protein isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein]
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA
13,14-dihydro-15-ketoprostaglandin D2 results in increased expression of CXCL2 protein 13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of CXCL2 mRNA]
13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR protein; 13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]
13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein]
9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA]
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]; NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]
NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of NGF mRNA]
[ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] ABCC1 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog ABCC1 protein affects the glutathionylation of 15-deoxy-delta(12,14)-prostaglandin J2
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]
[Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of CASP3 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP3 protein
CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CDKN1A 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1A protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of CHUK protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased phosphorylation of CHUK protein]
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased activity of EGR1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of EGR1 mRNA]
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Tretinoin] results in increased expression of FABP4 mRNA [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FABP4 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; wortmannin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; [ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GFAP 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of GFAP mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 affects the stability of HIF1A protein Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Dithiothreitol inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein; [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] ochratoxin A inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 protein
HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of HSF1 protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IFNG protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in decreased abundance of Prostaglandins]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1B protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with IL1B protein] results in decreased secretion of IL1B protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of IL1B protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PLIN1 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARA mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of INS mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein]
[Dexamethasone co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased secretion of LEP protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased secretion of LEP protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK1 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK1 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK3 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Dactinomycin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of MMP9 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased activity of NFE2L2 protein; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of NFE2L2 protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and affects the localization of NFE2L2 protein; manganese chloride inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NFE2L2 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased localization of NFKB1 protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of NFKBIA protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 affects the activity of NR3C1 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Dexamethasone binds to NR3C1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of PARP1 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of PARP1 protein
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PLIN1 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARA protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARA mRNA
15-deoxy-delta(12,14)-prostaglandin J2 affects the expression of PPARG PPARG protein mutant form results in decreased susceptibility to 15-deoxy-delta(12,14)-prostaglandin J2 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] 15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased expression of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in decreased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased localization of and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [deoxynivalenol results in increased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of PPARG mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; MG 262 promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PPARG protein
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]
PTGS1 protein promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PTGS2
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RARB
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of RELA protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride affects the localization of RELA protein]
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [peroxyvanadate results in increased phosphorylation of STAT1 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TG protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TGFB1 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [Alitretinoin results in decreased expression of TGFB1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[Alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; bisphenol A diglycidyl ether inhibits the reaction [[Alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased expression of TGFB1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased susceptibility to TGFB1 protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TLR2 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TNF protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]
16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein]
16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA]
Flurbiprofen inhibits the reaction [16,16-Dimethylprostaglandin E2 results in increased expression of PTGS2 mRNA] 16,16-Dimethylprostaglandin E2 inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA]
[HSD17B2 protein results in increased metabolism of and results in decreased activity of 2-methoxyestradiol] which results in increased chemical synthesis of 2-methoxyestrone
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of AKT1 protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of ARRB1 protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of BAD protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased expression of BAX protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2 protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2L1 protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of CASP3 protein AH 23848 inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein]
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased degradation of CTNNB1 protein
AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]
AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of GSK3B protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of IL1R1 protein
AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK1 protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK3 protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of PARP1 protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein]; AH 23848 binds to and results in decreased activity of PTGER4 protein
AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of RELA protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of SRC protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TNFRSF1A protein
ankaflavin results in increased expression of PPARA mRNA ankaflavin affects the reaction [PPARA protein affects the oxidation of Fatty Acids]; ankaflavin binds to and results in increased activity of PPARA protein
bardoxolone methyl affects the reaction [AMBRA1 protein affects the reaction [3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one inhibits the reaction [Doxorubicin results in decreased expression of PINK1 protein]]]; bardoxolone methyl affects the reaction [AMBRA1 protein affects the reaction [3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one inhibits the reaction [Doxorubicin results in decreased expression of PRKN protein]]]; bardoxolone methyl affects the reaction [AMBRA1 protein affects the reaction [3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one inhibits the reaction [Doxorubicin results in increased expression of SQSTM1 protein]]]
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL2 protein] bardoxolone methyl results in increased expression of CCL2 mRNA
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 mRNA]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 protein]
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL2 protein] bardoxolone methyl results in increased expression of CXCL2 mRNA
bardoxolone methyl results in increased expression of DDIT3 protein ochratoxin A promotes the reaction [bardoxolone methyl results in increased expression of DDIT3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A promotes the reaction [bardoxolone methyl results in increased expression of DDIT3 protein]]
bardoxolone methyl results in increased expression of GCLC mRNA; bardoxolone methyl results in increased expression of GCLC protein bardoxolone methyl results in decreased expression of GCLC mRNA
bardoxolone methyl results in increased expression of GCLM; bardoxolone methyl results in increased expression of GCLM mRNA bardoxolone methyl results in decreased expression of GCLM mRNA
GSK3B protein mutant form inhibits the reaction [bardoxolone methyl results in increased expression of HMOX1 protein]; GSK3B protein mutant form inhibits the reaction [bardoxolone methyl results in increased phosphorylation of GSK3B protein]
bardoxolone methyl inhibits the reaction [eriodictyol results in decreased expression of HMOX1 protein]; GSK3B protein mutant form inhibits the reaction [bardoxolone methyl results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [bardoxolone methyl results in increased expression of HMOX1 protein] bardoxolone methyl results in decreased expression of HMOX1 mRNA bardoxolone methyl results in increased expression of HMOX1 mRNA; bardoxolone methyl results in increased expression of HMOX1 protein [bardoxolone methyl co-treated with aristolochic acid I] results in increased expression of HMOX1 mRNA; bardoxolone methyl promotes the reaction [aristolochic acid I results in increased expression of HMOX1 protein]
bardoxolone methyl results in increased expression of HSPA5 protein ochratoxin A promotes the reaction [bardoxolone methyl results in increased expression of HSPA5 protein]
bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL10 protein]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]
bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of RELA protein]; bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein]
bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]
bardoxolone methyl results in increased expression of KEAP1 protein bardoxolone methyl results in decreased expression of KEAP1 mRNA bardoxolone methyl inhibits the reaction [aristolochic acid I results in increased expression of KEAP1 protein]
bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased susceptibility to LEP protein]; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of LEP protein]
bardoxolone methyl results in increased expression of NFE2L2 mRNA; bardoxolone methyl results in increased expression of NFE2L2 protein bardoxolone methyl inhibits the reaction [aristolochic acid I results in decreased expression of and affects the localization of NFE2L2 protein]; bardoxolone methyl inhibits the reaction [aristolochic acid I results in decreased expression of NFE2L2 mRNA] bardoxolone methyl results in increased localization of NFE2L2 protein NFE2L2 gene mutant form results in decreased susceptibility to bardoxolone methyl bardoxolone methyl inhibits the reaction [eriodictyol results in decreased phosphorylation of NFE2L2 protein]; bardoxolone methyl results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 promotes the reaction [bardoxolone methyl results in increased expression of SRXN1 protein]; NFE2L2 protein affects the reaction [bardoxolone methyl results in increased expression of HMOX1 protein] bardoxolone methyl results in increased activity of NFE2L2 protein
bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased expression of NFKBIA protein] bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; bardoxolone methyl inhibits the reaction [TNF protein affects the localization of NFKBIA protein]
bardoxolone methyl results in increased expression of NQO1 mRNA; bardoxolone methyl results in increased expression of NQO1 protein bardoxolone methyl inhibits the reaction [eriodictyol results in decreased expression of NQO1 protein] bardoxolone methyl results in decreased expression of NQO1 mRNA bardoxolone methyl results in increased activity of NQO1 protein [bardoxolone methyl co-treated with aristolochic acid I] results in increased expression of NQO1 mRNA; [bardoxolone methyl co-treated with aristolochic acid I] results in increased expression of NQO1 protein
bardoxolone methyl results in increased expression of PINK1 protein bardoxolone methyl affects the reaction [AMBRA1 protein affects the reaction [3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one inhibits the reaction [Doxorubicin results in decreased expression of PINK1 protein]]]
bardoxolone methyl affects the reaction [AMBRA1 protein affects the reaction [3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one inhibits the reaction [Doxorubicin results in decreased expression of PRKN protein]]]
bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of RELA protein]; bardoxolone methyl inhibits the reaction [TNF protein affects the localization of RELA protein]
bardoxolone methyl inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein] bardoxolone methyl results in decreased expression of RPS6 protein
bardoxolone methyl affects the expression of SQSTM1 mRNA bardoxolone methyl affects the reaction [AMBRA1 protein affects the reaction [3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one inhibits the reaction [Doxorubicin results in increased expression of SQSTM1 protein]]] bardoxolone methyl results in decreased expression of SQSTM1 mRNA
bardoxolone methyl results in increased expression of SRXN1 protein bardoxolone methyl results in decreased expression of SRXN1 mRNA bardoxolone methyl results in increased expression of SRXN1 mRNA; bardoxolone methyl results in increased expression of SRXN1 protein NFE2L2 promotes the reaction [bardoxolone methyl results in increased expression of SRXN1 protein]
[bardoxolone methyl co-treated with Dietary Fats] results in decreased expression of STAT3 protein; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of STAT3 protein] bardoxolone methyl results in decreased phosphorylation of STAT3 protein
bardoxolone methyl inhibits the reaction [TNF protein affects the localization of NFKBIA protein]; bardoxolone methyl inhibits the reaction [TNF protein affects the localization of RELA protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] [bardoxolone methyl co-treated with Dietary Fats] results in decreased expression of TNF protein; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of TNF protein]; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of TNF]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
bardoxolone methyl results in increased expression of TNFAIP3 mRNA; bardoxolone methyl results in increased expression of TNFAIP3 protein bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of VEGFA protein]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA] bardoxolone methyl results in decreased expression of VEGFA mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA
Camphor results in increased activity of TRPV3 protein isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein]
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA
AKR1C1 protein results in increased reduction of cyclopentanone NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone]
[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone]
[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone]
Esketamine results in increased expression of ATF4 mRNA; Esketamine results in increased expression of ATF4 protein N-Methylaspartate results in decreased expression of [Esketamine results in increased expression of ATF4 protein]
Esketamine affects the expression of BAX mRNA EIF2AK3 protein affects the reaction [Esketamine affects the expression of BAX mRNA]; N-Methylaspartate affects the reaction [Esketamine affects the expression of BAX mRNA] Esketamine results in increased expression of BAX protein
Esketamine results in decreased expression of BCL2 protein EIF2AK3 protein affects the reaction [Esketamine affects the expression of BCL2 mRNA]; N-Methylaspartate affects the reaction [Esketamine affects the expression of BCL2 mRNA]
Esketamine results in increased expression of DDIT3 mRNA; Esketamine results in increased expression of DDIT3 protein EIF2AK3 protein affects the reaction [Esketamine results in increased expression of DDIT3 mRNA]; N-Methylaspartate results in decreased expression of [Esketamine results in increased expression of DDIT3 protein]
EIF2AK3 protein affects the reaction [Esketamine affects the expression of BAX mRNA]; EIF2AK3 protein affects the reaction [Esketamine affects the expression of BCL2 mRNA]; EIF2AK3 protein affects the reaction [Esketamine results in increased expression of DDIT3 mRNA] Esketamine results in increased phosphorylation of EIF2AK3 protein Esketamine results in increased expression of EIF2AK3 mRNA
18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which affects the susceptibility to Vinblastine; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [Verapamil results in increased activity of ABCB1 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC1 mRNA] Glycyrrhetinic Acid results in increased activity of ABCC1 protein [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which affects the susceptibility to Doxorubicin; [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which results in increased abundance of fluorexon
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of BAX]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of BAX protein]; Glycyrrhetinic Acid promotes the reaction [bisphenol A results in increased expression of BAX protein] Glycyrrhetinic Acid results in decreased expression of BAX protein 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of BAX protein]
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in decreased expression of BCL2]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein] Glycyrrhetinic Acid results in decreased expression of BCL2 protein 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of BCL2 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA] Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in decreased activity of CAT protein]
Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in increased expression of CYCS protein] Glycyrrhetinic Acid results in decreased expression of CYCS protein
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of ERN1 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ERN1 mRNA]
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GPT protein] 18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of GPT protein]; Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of GPT protein]
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B2 protein Glycyrrhetinic Acid inhibits the reaction [tributyltin results in increased activity of HSD11B2 protein]; Glycyrrhetinic Acid inhibits the reaction [triphenyltin chloride results in increased activity of HSD11B2 protein]
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of IL1B protein]
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]
[Glycyrrhetinic Acid co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IRAK3 mRNA; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] Glycyrrhetinic Acid results in increased expression of IRAK3 protein
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
[Glycyrrhetinic Acid results in increased expression of NFE2L2] which results in decreased susceptibility to Carbon Tetrachloride; Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride affects the localization of NFE2L2 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of NFKBIA protein]
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of BAX protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of CDKN1B protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of BCL2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PPP1R12A protein]
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG protein]
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PPP1R12A protein]
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA protein]
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of TNF protein] 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]
hyperforin results in increased expression of ABCB1; hyperforin results in increased expression of ABCB1 mRNA hyperforin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]
hyperforin results in decreased expression of BAX mRNA hyperforin results in increased expression of BAX protein hyperforin inhibits the reaction [aluminum maltolate results in increased expression of BAX mRNA]
hyperforin inhibits the reaction [aluminum maltolate results in decreased expression of BCL2 mRNA] hyperforin results in increased expression of BCL2 mRNA
hyperforin inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CASP3 mRNA] hyperforin results in increased cleavage of CASP3 protein hyperforin results in decreased expression of CASP3 mRNA hyperforin inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CASP3 mRNA]; hyperforin inhibits the reaction [Propofol results in increased cleavage of CASP3 protein]
hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CYCS protein] hyperforin results in decreased expression of CYCS protein
hyperforin inhibits the reaction [CYP1A1 protein affects the metabolism of benzo(a)pyrene 7,8-dihydrodiol] hyperforin results in decreased activity of CYP1A1 protein
hyperforin results in increased expression of CYP3A4; hyperforin results in increased expression of CYP3A4 mRNA hyperforin results in increased expression of and results in increased activity of CYP3A4 protein hyperforin results in decreased activity of CYP3A4 protein
[NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin binds to and results in increased activity of NR1I2 protein; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; NR1I2 protein affects the reaction [hyperforin results in increased expression of CYP2C9 mRNA]; NR1I2 protein promotes the reaction [hyperforin results in increased abundance of Lipids] hyperforin binds to NR1I2 protein hyperforin results in increased activity of NR1I2 protein
hyperforin results in decreased expression of SLC22A1 protein [NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [Ketamine results in increased expression of ACTA2 protein] Ketamine results in increased expression of ACTA2 mRNA; Ketamine results in increased expression of ACTA2 protein
Ketamine results in decreased expression of AGT protein [ampullosporin co-treated with Ketamine] results in increased expression of AGT mRNA Ketamine results in increased expression of AGT mRNA
Ketamine results in decreased expression of AIF1 mRNA Ketamine results in decreased expression of AIF1 protein Cannabidiol inhibits the reaction [Ketamine results in decreased expression of AIF1 mRNA]
Ketamine results in increased expression of APP mRNA Ketamine results in decreased expression of and results in increased cleavage of APP protein; Monensin inhibits the reaction [Ketamine results in decreased expression of and results in increased cleavage of APP protein] [Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-40); [Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-42); Ketamine results in decreased expression of and results in increased cleavage of APP protein; Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-40)]; Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-42)]
Ketamine results in increased expression of BACE1 protein Ketamine results in increased expression of and affects the localization of BACE1 protein; Monensin inhibits the reaction [Ketamine results in increased expression of and affects the localization of BACE1 protein]
BAG5 protein inhibits the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of CASP3 mRNA]]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of BAG5 mRNA]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of BAG5 protein]; MIR22 affects the reaction [Ketamine results in increased expression of BAG5 mRNA]; MIR22 affects the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of BAG5 protein]]; MIR22 inhibits the reaction [Ketamine results in increased expression of BAG5 protein] Ketamine results in increased expression of BAG5 mRNA; Ketamine results in increased expression of BAG5 protein
Ketamine affects the localization of BAX protein Curcumin inhibits the reaction [Ketamine results in increased expression of BAX mRNA]; Curcumin inhibits the reaction [Ketamine results in increased expression of BAX protein]; TRPV4 protein affects the reaction [Ketamine results in increased expression of BAX mRNA]; TRPV4 protein affects the reaction [Ketamine results in increased expression of BAX protein] Ketamine results in increased expression of BAX mRNA; Ketamine results in increased expression of BAX protein
Curcumin affects the reaction [Ketamine results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [Ketamine results in decreased expression of BCL2 mRNA]; TRPV4 protein affects the reaction [Ketamine results in decreased expression of BCL2 mRNA]; TRPV4 protein affects the reaction [Ketamine results in decreased expression of BCL2 protein] LEP protein promotes the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in decreased expression of BCL2 protein]]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in decreased expression of BCL2 protein] Ketamine results in decreased expression of BCL2 mRNA; Ketamine results in decreased expression of BCL2 protein
Ketamine inhibits the reaction [Isoflurophate results in decreased expression of BDNF protein]; Ketamine inhibits the reaction [Pilocarpine results in increased expression of BDNF mRNA] Ketamine results in decreased expression of BDNF mRNA; Ketamine results in decreased expression of BDNF protein Ketamine results in increased expression of BDNF protein Sirolimus inhibits the reaction [Ketamine results in increased expression of BDNF protein]
Ketamine results in increased activity of CASP3 protein LEP protein promotes the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased cleavage of CASP3 protein]]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased cleavage of CASP3 protein] BAG5 protein inhibits the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of CASP3 mRNA]]; Curcumin inhibits the reaction [Ketamine results in increased expression of CASP3 mRNA]; Curcumin inhibits the reaction [Ketamine results in increased expression of CASP3 protein modified form]; Curcumin inhibits the reaction [Ketamine results in increased expression of CASP3 protein]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased activity of CASP3 protein]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of CASP3 mRNA]; Lithium inhibits the reaction [Ketamine results in increased cleavage of CASP3 protein]; MIR22 affects the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of CASP3 mRNA]]; MIR22 inhibits the reaction [Ketamine results in increased activity of CASP3 protein]; TRPV4 protein affects the reaction [Ketamine results in increased cleavage of CASP3 protein]; TRPV4 protein affects the reaction [Ketamine results in increased expression of CASP3 mRNA] Ketamine results in increased expression of CASP3 mRNA; Ketamine results in increased expression of CASP3 protein; Ketamine results in increased expression of CASP3 protein modified form
Ketamine results in increased activity of CASP9 protein lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased activity of CASP9 protein]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of CASP9 mRNA]; MIR22 inhibits the reaction [Ketamine results in increased activity of CASP9 protein]
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CCL5 mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CCL5 protein]
Ketamine results in decreased expression of CDH1 protein Ketamine results in decreased expression of CDH1 mRNA; Ketamine results in decreased expression of CDH1 protein 2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [Ketamine results in decreased expression of CDH1 protein]
Ketamine results in decreased phosphorylation of CREB1 protein Lithium inhibits the reaction [Ketamine results in decreased phosphorylation of CREB1 protein]
Ketamine results in increased expression of CTNNB1 protein Ketamine results in decreased expression of CTNNB1 protein Chir 99021 promotes the reaction [Ketamine results in increased expression of CTNNB1 protein]; Lithium inhibits the reaction [Ketamine results in decreased expression of CTNNB1 protein]
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CXCL1 mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CXCL1 protein]
Ketamine results in increased expression of CYP3A2 protein Ketamine results in decreased expression of CYP3A4 mRNA Ketamine results in decreased expression of and results in decreased activity of CYP3A4 protein
Ketamine results in increased expression of DDIT3 mRNA Ketamine results in increased expression of DDIT3 protein LEP protein promotes the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of DDIT3 protein]]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of DDIT3 protein]
Ketamine results in decreased expression of DLG4 protein Lithium inhibits the reaction [Ketamine results in decreased expression of DLG4 protein] Ketamine inhibits the reaction [Corticosterone results in decreased expression of DLG4 protein]; Sirolimus inhibits the reaction [Ketamine results in increased expression of DLG4 protein]
Ketamine results in increased expression of FN1 protein Ketamine results in increased expression of FN1 mRNA; Ketamine results in increased expression of FN1 protein 2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [Ketamine results in increased expression of FN1 protein]
Ketamine results in increased expression of GCLC mRNA Curcumin inhibits the reaction [Ketamine results in decreased expression of GCLC mRNA]; Curcumin inhibits the reaction [Ketamine results in decreased expression of GCLC protein] Ketamine results in decreased expression of GCLC mRNA; Ketamine results in decreased expression of GCLC protein
Ketamine results in decreased expression of GRIA1 protein Ketamine increases expression of Gria1 protein on hippocampal formation, prefrontal cortex cell surface Ketamine promotes the reaction [Methamphetamine increases expression of Gria1 protein in hippocampus, striatum] Ketamine inhibits the reaction [Corticosterone results in decreased expression of GRIA1 protein]; MAPT protein affects the reaction [Ketamine results in decreased expression of GRIA1 protein]
Ketamine inhibits the reaction [remifentanil results in increased phosphorylation of GRIN2B protein] Ketamine results in decreased expression of GRIN2B protein
Ketamine results in decreased phosphorylation of GSK3B protein Chir 99021 inhibits the reaction [Ketamine results in increased phosphorylation of GSK3B protein]; Lithium inhibits the reaction [Ketamine results in decreased phosphorylation of GSK3B protein]
Ketamine results in decreased expression of HMOX1 mRNA; Ketamine results in decreased expression of HMOX1 protein Curcumin inhibits the reaction [Ketamine results in decreased expression of HMOX1 mRNA]; Curcumin inhibits the reaction [Ketamine results in decreased expression of HMOX1 protein]
Ketamine results in decreased expression of HSPA5 mRNA Ketamine results in increased expression of HSPA5 protein LEP protein promotes the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of HSPA5 protein]]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of HSPA5 protein] Ketamine affects the expression of HSPA5 mRNA
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of ICAM1 mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of ICAM1 protein]
Ketamine results in increased expression of IL1B mRNA; Ketamine results in increased expression of IL1B protein Ketamine results in increased secretion of IL1B protein [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of IL1B mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of IL1B protein]; Ketamine inhibits the reaction [Acetaminophen results in increased expression of IL1B protein]; Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; TLR4 mutant form promotes the reaction [Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; TLR4 mutant form promotes the reaction [Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]] Ozone inhibits the reaction [Ketamine results in increased expression of IL1B mRNA]; TRPV4 protein affects the reaction [Ketamine results in increased expression of IL1B protein]
Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] TRPV4 protein affects the reaction [Ketamine results in increased expression of IL6 protein] [Atropine co-treated with Ketamine] inhibits the reaction [Soman results in increased expression of IL6 mRNA]; [Atropine co-treated with Ketamine] inhibits the reaction [Soman results in increased expression of IL6 protein]; Ketamine inhibits the reaction [Acetaminophen results in increased expression of IL6 protein]; Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; mangiferin inhibits the reaction [Ketamine results in increased expression of IL6 protein] Ketamine results in increased expression of IL6 mRNA; Ketamine results in increased expression of IL6 protein IL6 affects the susceptibility to Ketamine
LEP protein promotes the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in decreased expression of BCL2 protein]]; LEP protein promotes the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased cleavage of CASP3 protein]]; LEP protein promotes the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of DDIT3 protein]]; LEP protein promotes the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of HSPA5 protein]]; lipoxin A4 methyl ester inhibits the reaction [Ketamine results in decreased expression of LEP protein]
Ketamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Ketamine results in decreased phosphorylation of MAPK1 protein Lithium inhibits the reaction [Ketamine results in decreased phosphorylation of MAPK1 protein]
Ketamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Lithium inhibits the reaction [Ketamine results in decreased phosphorylation of MAPK3 protein]
Ketamine results in increased phosphorylation of MAPT protein MAPT protein affects the reaction [Ketamine results in decreased expression of GRIA1 protein]; MAPT protein affects the reaction [Ketamine results in decreased expression of GRIA2 protein]
Ketamine results in decreased expression of MIR22 mRNA lipoxin A4 methyl ester inhibits the reaction [Ketamine results in decreased expression of MIR22 mRNA]; MIR22 affects the reaction [Ketamine results in increased expression of BAG5 mRNA]; MIR22 affects the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of BAG5 protein]]; MIR22 affects the reaction [lipoxin A4 methyl ester inhibits the reaction [Ketamine results in increased expression of CASP3 mRNA]]; MIR22 inhibits the reaction [Ketamine results in increased activity of CASP3 protein]; MIR22 inhibits the reaction [Ketamine results in increased activity of CASP9 protein]; MIR22 inhibits the reaction [Ketamine results in increased expression of BAG5 protein]
Ketamine results in decreased expression of NFE2L2 mRNA; Ketamine results in decreased expression of NFE2L2 protein; Ketamine results in decreased expression of NFE2L2 protein modified form Curcumin inhibits the reaction [Ketamine results in decreased expression of NFE2L2 mRNA]; Curcumin inhibits the reaction [Ketamine results in decreased expression of NFE2L2 protein modified form]; Curcumin inhibits the reaction [Ketamine results in decreased expression of NFE2L2 protein]
Ketamine results in increased expression of NFKBIA mRNA Ketamine results in increased phosphorylation of NFKBIA protein TRPV4 protein affects the reaction [Ketamine results in increased phosphorylation of NFKBIA protein]
Ketamine results in decreased expression of NQO1 mRNA; Ketamine results in decreased expression of NQO1 protein Curcumin inhibits the reaction [Ketamine results in decreased expression of NQO1 mRNA]; Curcumin inhibits the reaction [Ketamine results in decreased expression of NQO1 protein]
Ketamine inhibits the reaction [Pilocarpine results in increased expression of NTRK2 mRNA] Ketamine inhibits the reaction [NTRK2 protein binds to AP2M1 protein]
acetovanillone inhibits the reaction [Ketamine results in decreased expression of PVALB protein] [ampullosporin co-treated with Ketamine] results in increased expression of PVALB mRNA
Ketamine results in increased phosphorylation of RELA protein TRPV4 protein affects the reaction [Ketamine results in increased phosphorylation of RELA protein]
Ketamine inhibits the reaction [Corticosterone results in decreased expression of SYN1 protein]; Sirolimus inhibits the reaction [Ketamine results in increased expression of SYN1 protein]
Ketamine results in increased expression of TGFB1 protein Ketamine results in increased expression of TGFB1 mRNA Ketamine results in increased secretion of TGFB1 protein
TLR4 mutant form promotes the reaction [Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; TLR4 mutant form promotes the reaction [Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]
Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] Ketamine results in increased expression of TNF protein Ketamine co-treated with xylazine inhibits the reaction [lipopolysaccharide increases expression of Tnf protein in serum and mucosa of stomach] [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of TNF mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of TNF protein]; Ketamine inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; Ketamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] Ozone inhibits the reaction [Ketamine results in decreased expression of TNF mRNA]; TRPV4 protein affects the reaction [Ketamine results in increased expression of TNF protein]
Ketamine results in decreased expression of TRPC3 mRNA; Ketamine results in decreased expression of TRPC3 protein Chir 99021 promotes the reaction [Ketamine results in decreased expression of TRPC3 protein]
Ketamine results in increased expression of TRPV4 mRNA; Ketamine results in increased expression of TRPV4 protein TRPV4 protein affects the reaction [Ketamine results in decreased activity of CAT protein]; TRPV4 protein affects the reaction [Ketamine results in decreased expression of BCL2 mRNA]; TRPV4 protein affects the reaction [Ketamine results in decreased expression of BCL2 protein]; TRPV4 protein affects the reaction [Ketamine results in increased cleavage of CASP3 protein]; TRPV4 protein affects the reaction [Ketamine results in increased expression of BAX mRNA]; TRPV4 protein affects the reaction [Ketamine results in increased expression of BAX protein]; TRPV4 protein affects the reaction [Ketamine results in increased expression of CASP3 mRNA]; TRPV4 protein affects the reaction [Ketamine results in increased expression of IL1B protein]; TRPV4 protein affects the reaction [Ketamine results in increased expression of IL6 protein]; TRPV4 protein affects the reaction [Ketamine results in increased expression of TNF protein]; TRPV4 protein affects the reaction [Ketamine results in increased phosphorylation of NFKBIA protein]; TRPV4 protein affects the reaction [Ketamine results in increased phosphorylation of RELA protein]
[Ketamine co-treated with Midazolam co-treated with Valproic Acid] inhibits the reaction [[Sarin co-treated with [Atropine co-treated with trimethylene-bis(4-hydroxyiminomethylpyridinium)]] results in increased expression of TSPO protein]
Ketamine results in increased expression of VIM mRNA 2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [Ketamine results in increased expression of VIM protein]
lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of ADAM17 mRNA]; lactucin inhibits the reaction [Fatty Acids, Nonesterified results in increased expression of ADAM17 mRNA]
lactucin results in increased expression of and results in decreased phosphorylation of AKT1 protein lactucin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]
Acetylcysteine inhibits the reaction [lactucin results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [lactucin results in decreased expression of BCL2 protein] lactucin results in decreased expression of BCL2 mRNA; lactucin results in decreased expression of BCL2 protein
lactucin affects the reaction [Dietary Fats affects the expression of CEBPA mRNA]; lactucin affects the reaction [Dietary Fats affects the expression of CEBPA protein]
Acetylcysteine inhibits the reaction [lactucin results in decreased expression of CFLAR protein]; CFLAR protein inhibits the reaction [lactucin results in increased cleavage of PARP1 protein]; lactucin results in decreased expression of and results in increased degradation of CFLAR protein
lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA mRNA]; lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA protein]; lactucin inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of HADHA mRNA]; lactucin inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of HADHA protein]
lactucin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
lactucin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]
lactucin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] lactucin results in increased expression of and results in decreased phosphorylation of MAPK1 protein
lactucin results in increased expression of and results in decreased phosphorylation of MAPK3 protein lactucin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]
lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [lactucin results in increased cleavage of PARP1 protein]; CFLAR protein inhibits the reaction [lactucin results in increased cleavage of PARP1 protein]
lactucin affects the reaction [Dietary Fats affects the expression of PPARG mRNA]; lactucin affects the reaction [Dietary Fats affects the expression of PPARG protein]
lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of SQSTM1 mRNA]; lactucin inhibits the reaction [Fatty Acids, Nonesterified results in increased expression of SQSTM1 mRNA]
lactucin results in decreased localization of STAT3 protein; lactucin results in decreased localization of STAT3 protein modified form lactucin affects the reaction [Dietary Fats affects the phosphorylation of STAT3 protein]
loxoprofen metabolite results in increased expression of CLDN1 protein; loxoprofen results in increased expression of CLDN1 mRNA; loxoprofen results in increased expression of CLDN1 protein
loxoprofen metabolite results in increased expression of CLDN3 protein; loxoprofen results in increased expression of CLDN3 mRNA; loxoprofen results in increased expression of CLDN3 protein
loxoprofen metabolite results in increased expression of CLDN5 protein; loxoprofen results in increased expression of CLDN5 mRNA; loxoprofen results in increased expression of CLDN5 protein
[nitisinone results in decreased activity of HPD protein] which results in decreased expression of GCLC mRNA; [nitisinone results in decreased activity of HPD protein] which results in decreased expression of GCLM mRNA; [nitisinone results in decreased activity of HPD protein] which results in decreased expression of HMOX1 mRNA; [nitisinone results in decreased activity of HPD protein] which results in decreased expression of NQO1 mRNA
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; [omaveloxolone co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]
AKR1C3 protein results in increased metabolism of Prostaglandin D2 AKR1C3 protein results in increased reduction of Prostaglandin D2 AKR1C3 protein results in decreased susceptibility to Prostaglandin D2 AKR1C3 protein results in decreased metabolism of Prostaglandin D2 [AKR1C3 protein results in decreased metabolism of Prostaglandin D2] which results in decreased chemical synthesis of 9-deoxy-delta-9-prostaglandin D2; [AKR1C3 protein results in increased reduction of Prostaglandin D2] which results in increased chemical synthesis of Dinoprost; [Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]
APP protein modified form results in increased secretion of Prostaglandin D2 CNB 001 inhibits the reaction [APP protein modified form results in increased secretion of Prostaglandin D2]; Dronabinol inhibits the reaction [APP protein modified form results in increased secretion of Prostaglandin D2]; L 685458 inhibits the reaction [APP protein modified form results in increased secretion of Prostaglandin D2]
[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of CXCL2 protein; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of CXCL2 protein] Prostaglandin D2 results in increased expression of CXCL2 protein
[4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine results in increased expression of HPGDS mRNA] which results in decreased abundance of Prostaglandin D2
[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Prostaglandin D2; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Prostaglandin D2]; resveratrol inhibits the reaction [IL1B protein results in increased abundance of Prostaglandin D2] Prostaglandin D2 results in increased expression of IL1B protein [Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL1B protein; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL1B protein] IL1B protein results in increased secretion of Prostaglandin D2 IL1B protein promotes the reaction [rosiglitazone results in increased secretion of Prostaglandin D2]
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]
[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL6 protein; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL6 protein]
Prostaglandin D2 affects the localization of and results in increased expression of PPARG protein Prostaglandin D2 affects the localization of PPARG protein
13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; adenosine 5'-O-(3-thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Adenylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Alprostadil inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; BW 245C inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; BW A868C inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; delta(12)-prostaglandin J(2) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Dinoprost inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Dinoprostone inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Guanosine 5'-O-(3-Thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Guanylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Iloprost inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; L 644698 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Prostaglandin D2 binds to and results in increased activity of PTGDR protein; ZK 110841 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] [Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased metabolism of Adenosine; [Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased secretion of Adenosine; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of CXCL2 protein]; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL1B protein]; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL6 protein]
Endocannabinoids inhibits the reaction [Prostaglandin D2 binds to and results in increased activity of PTGDR2 protein]; Prostaglandin D2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [Prostaglandin D2 binds to and results in increased activity of PTGDR2 protein] Prostaglandin D2 results in increased activity of PTGDR2 protein 13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; 5-hydroxyindomethacin inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; Indomethacin inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; ramatroban inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; sulindac sulfide inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; zomepirac inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]
[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [2-phenylphenol binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Acetaminophen results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Prostaglandin D2; [Chlorpropham binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [cypermethrin binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [cyprodinil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [enilconazole binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [fludioxonil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Ibuprofen binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Linuron binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Methiocarb binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Nanotubes, Carbon co-treated with PTGS2 gene mutant form] results in increased abundance of Prostaglandin D2; [pirimiphos methyl binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Prostaglandin D2; [PTGS2 gene mutant form results in increased susceptibility to Nanotubes, Carbon] which results in increased abundance of Prostaglandin D2; [pyrimethanil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [tebuconazole binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2
Prostaglandin D2 promotes the reaction [TSHB protein results in increased expression of TG protein] Prostaglandin D2 results in increased expression of TG protein
[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Prostaglandin D2; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Prostaglandin D2] TNF protein results in increased abundance of Prostaglandin D2
Prostaglandin D2 results in increased expression of TNFRSF11B mRNA Prostaglandin D2 results in increased secretion of TNFRSF11B protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]; resveratrol inhibits the reaction [Prostaglandin D2 results in increased expression of TNFRSF11B mRNA]; resveratrol inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]; SRT1720 inhibits the reaction [Prostaglandin D2 results in increased expression of TNFRSF11B mRNA]; SRT1720 inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]
[9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] which results in increased expression of ABCA1 mRNA
[9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]
9-deoxy-delta-9-prostaglandin D2 results in increased activity of CASP3 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of CASP3 protein
9-deoxy-delta-9-prostaglandin D2 promotes the reaction [arsenite results in increased expression of CRYAB mRNA]; 9-deoxy-delta-9-prostaglandin D2 promotes the reaction [arsenite results in increased expression of CRYAB protein]
9-deoxy-delta-9-prostaglandin D2 results in increased expression of GCLC mRNA; 9-deoxy-delta-9-prostaglandin D2 results in increased expression of GCLC protein
9-deoxy-delta-9-prostaglandin D2 results in increased expression of GCLM mRNA; 9-deoxy-delta-9-prostaglandin D2 results in increased expression of GCLM protein
[2-chloro-5-nitrobenzanilide results in decreased activity of PPARG protein] inhibits the reaction [9-deoxy-delta-9-prostaglandin D2 results in increased expression of GDF15 protein] 9-deoxy-delta-9-prostaglandin D2 results in increased expression of GDF15 mRNA; 9-deoxy-delta-9-prostaglandin D2 results in increased expression of GDF15 protein
[9-deoxy-delta-9-prostaglandin D2 co-treated with alitretinoin] promotes the reaction [[PPARG protein binds to RXRA protein] which binds to GSTA2 promoter]; [9-deoxy-delta-9-prostaglandin D2 co-treated with alitretinoin] results in increased expression of GSTA2 mRNA; [9-deoxy-delta-9-prostaglandin D2 co-treated with alitretinoin] results in increased expression of GSTA2 protein GSTA2 protein affects the metabolism of 9-deoxy-delta-9-prostaglandin D2 9-deoxy-delta-9-prostaglandin D2 results in increased expression of GSTA2 protein
[9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] which results in increased expression of NR1H3 mRNA
9-deoxy-delta-9-prostaglandin D2 results in increased cleavage of PARP1 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of PARP1 protein
9-deoxy-delta-9-prostaglandin D2 results in increased activity of PPARG protein 9-deoxy-delta-9-prostaglandin D2 results in increased expression of PPARG mRNA 9-deoxy-delta-9-prostaglandin D2 promotes the reaction [PPARG protein alternative form results in decreased activity of SLC2A4 promoter]; [9-deoxy-delta-9-prostaglandin D2 co-treated with Alitretinoin] promotes the reaction [[PPARG protein binds to RXRA protein] which binds to GSTA2 promoter] 9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein; [2-chloro-5-nitrobenzanilide results in decreased activity of PPARG protein] inhibits the reaction [9-deoxy-delta-9-prostaglandin D2 results in increased expression of GDF15 protein]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] which results in increased expression of ABCA1 mRNA; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] which results in increased expression of NR1H3 mRNA; Ethanol inhibits the reaction [9-deoxy-delta-9-prostaglandin D2 results in increased activity of PPARG protein]
9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PTGDR protein; 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]
[9-deoxy-delta-9-prostaglandin D2 co-treated with alitretinoin] promotes the reaction [[PPARG protein binds to RXRA protein] which binds to GSTA2 promoter]
9-deoxy-delta-9-prostaglandin D2 promotes the reaction [TSHB protein results in increased expression of TG protein] 9-deoxy-delta-9-prostaglandin D2 results in increased expression of TG protein
rubiarbonone C results in decreased activity of CYP4F3 protein alternative form rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid]
browse the term
